BioMarin director granted 7,490 RSUs in Form 4

Dere Willard H reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Dere Willard H reported acquisition or exercise transactions in this Form 4 filing.

BIOMARIN PHARMACEUTICAL INC director Willard H. Dere received a grant of 7,490 shares of common stock in the form of restricted stock units on June 2, 2026. The grant is recorded at a price of $0.00 per share, reflecting that it is a compensation award rather than a market purchase.

Following this award, Dere directly holds 46,440 shares of BioMarin common stock as reported in this filing. The footnotes clarify that the transaction represents restricted stock units, with price not applicable.

Insider Trade Summary

Grant/Award: 7,490 shares

Grant/Award 1 txn

Insider Dere Willard H

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7,490	$0.00	$0.00

Holdings After Transaction: Common Stock — 46,440 shares (Direct)

Footnotes (1)

1. F1. Restricted stock units granted on June 2, 2026. Price not applicable.

Key Figures

RSU grant size: 7,490 shares Reported grant price: $0.00 per share Shares held after grant: 46,440 shares +1 more

4 metrics

RSU grant size 7,490 shares Restricted stock units granted on June 2, 2026

Reported grant price $0.00 per share Compensation award, price not applicable per footnote

Shares held after grant 46,440 shares Total direct BioMarin common stock holdings after transaction

Acquisition transactions 1 transaction Form 4 shows one acquisition-type entry (code A)

Key Terms

Restricted stock units, Form 4, Grant, award, or other acquisition, Common Stock

4 terms

Restricted stock units financial

"Restricted stock units granted on June 2, 2026."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Form 4 regulatory

"According to a new Form 4."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Grant, award, or other acquisition financial

"transaction code description is Grant, award, or other acquisition."

Common Stock financial

"security title is Common Stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BioMarin (BMRN) report for Willard H. Dere?

BioMarin reported that director Willard H. Dere received 7,490 shares as a restricted stock unit grant. This is a compensation-related equity award, not an open-market stock purchase or sale, and was dated June 2, 2026.

How many BioMarin (BMRN) shares does Willard H. Dere hold after this Form 4?

After the award, Willard H. Dere is reported to directly hold 46,440 shares of BioMarin common stock. This total includes the newly granted 7,490 restricted stock units recorded in the June 2, 2026 transaction.

Was the BioMarin (BMRN) Form 4 transaction an open-market buy or sell?

The Form 4 shows a grant coded as an acquisition (A), representing 7,490 restricted stock units. The price is listed as $0.00 per share, indicating a compensation grant rather than an open-market purchase or sale.

What does the footnote on the BioMarin (BMRN) Form 4 transaction explain?

The footnote explains that the 7,490 units are restricted stock units granted on June 2, 2026, and that price is not applicable. This clarifies the award is a stock-based compensation grant with no cash price per share.

How is the Form 4 transaction for BioMarin (BMRN) classified by the SEC code?

The transaction uses code A, which stands for a grant, award, or other acquisition. This confirms the 7,490-share entry is a non-derivative equity award to Willard H. Dere rather than a market trade in BioMarin shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 06:04 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dere Willard H

(Last) (First) (Middle)

C/O BIOMARIN PHARMACEUTICAL INC.

770 LINDARO STREET

(Street)

SAN RAFAEL CALIFORNIA 94901

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/02/2026		A		7,490	A	$0(1)	46,440	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock units granted on June 2, 2026. Price not applicable.

Remarks:

	/s/ Tae Sang Yoo, Attorney-in-Fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)